Who we are
The Company
Phymtech was born from the idea of its founders to export to the pharmacological field their know-how and long-term experience in Physics and Mathematics. Phymtech's expertise is based on solid capabilities in
- mathematical modelling of physical processes
- analysis of large multidimensional data
- studying of complex systems
- project managing
- problem solving
Our mission
Phymtech main interest is personalized medicine obtained through a therapy personalization achieved in terms of both drug and dose selection.
The role of genetic polymorphisms as well as of clinical and biological covariates on the efficacy and toxicity of selected drugs is studied by means of population statistics which paves the way to patient stratification.
Other fields of interest are drug discovery and the so-called in silico investigations.
Phymtech carries out each task utilizing its own staff and collaborations with experts from University of Pisa and National Research Council.
Some of our recent works
- The hOCT1/ABCB1 Diplotype is Associated with Complete Cytogenetic Response and Tolerability to Imatinib in Patients Affected by Chronic Myeloid Leukemia.
Presented at the 21st Congress of the European Hematology Association, Copenaghen June 9-12, 2016
- Blood Dec 2015, 126 (23) 4838
Combined Famd and ANOVA Investigation Leads to Significant Association Between the hOCT1/ABCB1 Diplotype and Both Efficacy and Tolerability in Patients Affected By Chronic Myeloid Leukemia.
57th ASH Annual Meeting and Exposition
- Blood Dec 2014, 124 (21) 3608
Transmembrane Transporters hOCT1 and SLCO1B3 Polymorphisms Could Have a Role in Patients Affected By Chronic Myeloid Leukemia Treated with Nilotinib.
56th ASH Annual Meeting and Exposition.
- Haematologica October 2014 99: S1-S113
Combined unfavourable polymorphisms of hOCT1 and ABCG2 are responsible for a delayed complete cytogenetic response during imatinib treatment.
XIII Congress Of The Italian Society Of Experimental Hematology
Collaborations
